Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2003

View Archived Issues

Improved angiographic diagnosis reported with gadofosveset sodium

Evidence of antitumor activity for Xcellerated T-cells and IL-2 in renal cell carcinoma

Drug-induced hypothermia protects against ischemic damage to the brain

Cethromycin has superior efficacy compared to erythromycin against enterococci in vitro and in vivo

Second- and third-generation oral contraceptives used in female hirsutism

Antiinflammatory effects described for thalidomide in sepsis

News-breaking molecule: the first and only reported potent inhibitor of human asparagine synthase

Two novel series of S1P1/edg1 agonists reported by Merck & Co.

Euroceltique claims new modulators of VR1 and/or mGluR receptors

Merck KGaA scientists discover new factor Xa/factor VIIa inhibitors

Novel 5-HT1A agonists with utility as antipsychotics and in Parkinson's disease therapy

4SC presents potassium channel modulators for respiratory disorders and other uses

Novel heparanase inhibitors and their use as antitumor agents described in recent patent

CV Therapeutics patent covers adenosine A1 agonists for arrhythmia, heart failure, etc.

New phase III trial of Humira in psoriatic arthritis

SBIR grant supports development of ALTU-140 for chronic abdominal pain

Improved vision observed in phase I/II trial of squalamine in wet AMD

Orphan drug grant awarded in support of Veronate

Enrollment under way in pivotal trial of iseganan for VAP

MT-100 NDA accepted for filing

Efficacy reported in phase II trial of IL-1 Trap for RA

Development of SCV-07 oral formulation receives funding

Orally active Syk inhibitor exerts antiinflammatory effects in rodent model of asthma

Bactericidal effects described for TD-6424 against Gram-positive strains

Anti-HIV pyridine oxide derivatives may have second target in addition to RT

Highly specific GSK-3beta inhibitor from AstraZeneca with neuroprotective effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...